EXPANDed studies analysis, presented by R. Estevez-Loureiro
TR reduction in patients treated for MR with MitraClip™ TEER (without additional tricuspid intervention) in the EXPANDed studies was associated with significant quality-of-life improvement and lower mortality at 1 year. MitraClip™ TEER is not indicated for the treatment of TR nor TR patients.
LEARN MORE:
Related Resources
TRILUMINATE Pivotal - 2-year update EuroPCR 25
bRIGHT 2-year real-world outcomes
Poster: Primary MR in the Very Elderly
PCR LV 2021: Navitor™ Live-in-a-box
Navitor Valve in small aortic annuli
Epic Mitral – 10-Year Clinical Outcomes
PCR LV 2021: Navitor™ Looking ahead
TEER G5 Brochure 2025
Data Summary PFO closure in patients > 60 Years
TRENDING TOPICS
TEER G5 Brochure 2025
Poster: Primary MR in the Very Elderly
TRILUMINATE Pivotal - 2-year update EuroPCR 25
